Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2026-01-06 @ 4:16 AM
Study NCT ID:
NCT01866293
Status:
COMPLETED
Last Update Posted:
2017-08-30
First Post:
2013-05-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-05-28
Start Date Type:
None
Primary Completion Date:
2016-08-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-08-18
Completion Date Type:
ACTUAL
First Submit Date:
2013-05-28
First Submit QC Date:
None
Study First Post Date:
2013-05-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-08-01
Results First Submit QC Date:
None
Results First Post Date:
2017-08-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-08-01
Last Update Post Date:
2017-08-30
Last Update Post Date Type:
ACTUAL